Red blood cells as modulators to T cell growth and survival

Current Pharmaceutical Design

Volumn 10, Issue 2, 2004, Pages 191-201

  Arosa, Fernando A ^a,b   Pereira, Carlos F ^a   Fonseca, Ana M ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Apoptosis; CD4+; CD8+; Growth; Iron; Red blood cell; ROS; Survival; T cell

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; FERRITIN; FLICE INHIBITORY PROTEIN; HEME OXYGENASE 1; PHYTOHEMAGGLUTININ P; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANEMIA; BLOOD TRANSFUSION; CARBON DIOXIDE TRANSPORT; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; HEMOPHILIA; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THALASSEMIA; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIGENS, CD4; BLOOD TRANSFUSION; CELL DIVISION; CELL SURVIVAL; ERYTHROCYTES; HUMANS; IRON; MONOCYTES; T-LYMPHOCYTES;

EID: 0347286785     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453432     Document Type: Review

References (176)

1. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999; 17:221-53.
2. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K, et al. The interleukin-2 receptor γchain: its role in the multiple cytokine receptor complexes and T cell development. Annu Rev Immunol 1996; 14: 179-205.
3. Freitas AA, Rocha B. Population biology of lymphocytes: the flight for survival. Annu Rev Immunol 2000; 18: 83-111.
4. Pawelec G, Hirokawa K, Fulop T. Altered T cell signaling in ageing. Mech Ageing Dev 2001; 122: 1613-37.
5. Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today 1999; 20: 302-06.
6. Kmiec, Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 200 1; 161: 1-151.
7. Brittenham GM. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, Eds. The red cell cycle. London, UK, Saunders 1994; 31-62.
8. Arosa FA. CD8+CD28- T cells: certainties and uncertainties of a prevalent human T cell subset. Immunol Cell Biol 2003; 80: 1-13.
9. Halliwell B, Gutteridge JMC. In: Halliwell B, Gutteridge JMC, Eds. Free Radicals in Biology and Medicine. Oxford University Press, New York, 1999; 485-543.
10. Lynch RE, Fridovich I. Permeation of the erythrocyte stroma by superoxide radical. J Biol Chem 1978; 253: 4697-9.
11. Winterboum CC, Stern A. Human red cells scavenge extracellular hydrogen peroxide and inhibit formation of hypochlorous acid and hydroxyl radical. J Clin Invest 1987; 80: 1486-91.
12. Denicola A, Souza JM, Radi R. Diffusion of peroxynitrite across erythrocyte membranes. Proc Natl Acad Sci USA 1998; 95: 3566-71.
13. Pawloski JR, Hess DT, Stamler JS. Export by red blood cells of nitric oxide bioactivity. Nature 2001; 409: 622-6.
14. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, et al. Nitric oxide in the human respiratory cycle. Nat Med 2002; 8: 711-7
15. Pawloski JR, Stamler JS. Nitric oxide in RBCs. Transfusion 2002; 42: 1603-9.
16. Hobbs AJ, Gladwin MT, Patel RP, Williams DLH, Butler AR. Haemoglobin: NO transporter, NO inactivator or None of the above? Trends Pharmacol Sci 2002; 23: 406-11.
17. Pawloski JR, Swaminathan RV, Stamler JS. Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. Circulation 1998; 97: 263-7.
18. Megson IL, Sogo N, Mazzei FA, Butler AR, Walton JC, Webb DJ. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol 2000; 131: 1391-8.
19. Vallés MT, Santos MT, Aznar J, Martinez M, Moscardo A, Piñón M, et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 2002; 99: 3978-84.
20. Aoshiba K, Nakajima Y, Yasui S, Tamaoki J, Nagai A. Red blood cells inhibit apoptosis of human neutrophils. Blood 1999; 93: 4006-10.
21. Matsuoka I, Fujino Y, Ogita S, Inoue M. Impact of erythrocytes on mouse embryonal development in vitro. FEBS Lett 1995; 371: 297-9.
22. Brown JM, Grosso MA, Terada LS, Beehler CJ, Toth KM, Whitman GJ, et al. Erythrocytes decrease myocardial hydrogen peroxide levels and reperfusion injury Am J Physiol 1989; 256: H584-8.
23. Melder RJ, Munn LL, Yamada S, Ohkubo C, Jain RK. Selectin- and integrin-mediated T-lymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes. Biophys J 1995;69:2131-8.
24. Munn LL, Melder RJ, Jain RK. Role of erythrocytes in leukocyte-endothelial interactions: mathematical model and experimental validation. Biophys J 1996; 71:466-78.
25. Melder RJ, Yuan J, Munn LL, Jain RK. Erythrocytes enhance lymphocyte rolling and arrest in vivo. Microvasc Res 2000; 59: 316-22.
26. Agar NS, Sadrzadeh SM, Hallaway PE, Eaton JW. Erythrocyte catalase. A somatic oxidant defense? J Clin Invest 1986; 77: 319-21.
27. Scott MD, Lubin BH, Zuo L, Kuypers FA. Erythrocyte defense against hydrogen peroxide: preeminent importance of catalase. Lab Clin Med 1991; 118: 7-16.
28. Richards RS, Roberts TK, Dunstan RH, McGregor NR, Butt HL. Erythrocyte antioxidant systems protect cultured endothelial cells against oxidant damage. Biochem Mol Biol Int 1998; 46: 857-65.
29. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5:253-9.
30. Fischer E, Lenhard V, Seifert P, Kluge A, Johannsen R. Blood transfusion-induced suppression of cellular immunity in man. Human Immunol 1980; 3:187-94.
31. Triulzi DJ, Vanek K, Ryan DH, Blumberg N. A clinical and immunologic study of blood transfusion and postoperative infection in spinal surgery. Transfusion 1992; 32: 517-24.
32. Heiss MM, Jauch KW, Delanoff C, Jauch KW, Gahka C, Mempel M, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12: 1859-67.
33. Jensen LS, Kissmeyer-Nielsen P, Wolff B. Randomised comparision of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841-5.
34. Claas FH, Roelen DL, van Rood JJ, Brand A. Modulation of the alloimmune response by blood transfusions. Transfus Clin Biol 2001; 8: 315-7.
35. Brand A. Immunological aspects of blood transfusions. Transpl Immunol 2002; 10: 183-90.
36. Prince HE. The significance of T lymphocytes in transfusion medicine. Transfus Med Rev 1992; 6: 32-43.
37. Tartter PL. Immunological effects of blood transfusion. Immunol Invest 1995; 24: 277-88.
38. Oksanen K, Kekomaki R, Ruutu T, Koskimies S, Myllyla G. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion 1991; 31: 588-94.
39. Dzieczkowski JS, Barrett BB, Nester D, Campbell M, Cook J, Sugrue M, et al. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995; 35: 20-5.
40. Innerhofer P, Luz G, Spotl L, Hobisch-Hagen P, Schobersberger W, Fischer M, et al. Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus white cell-reduced blood to patients undergoing arthroplasty. I. Proliferative T-cell responses and the balance of helper and suppressor T cells. Transfusion 1999; 39: 1089-96.
41. Fergusson D, Hebert PC, Barrington KJ, Shapiro SH. Effectiveness of WBC reduction in neonates: what is the evidence of benefit? Transfusion 2002; 42: 159-65.
42. Lane TA, Gernsheimer T, Mohandas K, Assmann SF. Signs and symptoms associated with the transfusion of WBC-reduced RBCs and non-WBC-reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study. Transfusion 2002; 42: 265-74.
43. Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114-22.
44. Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood 1984; 64: 308-10.
45. Grady RW, Akbar AN, Giardine PJ, Hilgartner MW, de Sousa M. Disproportionate lymphoid cell subsets in thalassemia major: the relative contributions of transfusion and splenectomy. Brit J Haematol 1985; 59:713-24.
46. Dwyer J, Wood C, McNamara J, Williams A, Andiman W, Rink L, et al. Abnormalities in the immune system of children with beta-thalassemia major. Clin Exp Immunol 1987; 68: 621-9.
47. Pardalos G, Kannakoudi-Tsakalidis F, Malaka-Zafirin M, Tsantali H, Papaevangelou G. Iron-related disturbances of cell mediated immunity in multitransfused children with thalassemia major. Clin Exp Immunol 1987; 68: 138-45.
48. Neri A, Brugiatelli M, Iacopino P, Callea V, Ronco F. Natural killer cell activity and T subpopulations in thalassemia major. Acta Haematol 1984; 71:263-9.
49. Guglielmo P, Cunsolo F, Lombardo T, Sortino G, Giustolisi R, Cacciola E, et al. T-subset abnormalities in thalassaemia intermedia: possible evidence for a thymus functional deficiency. Acta Haematol 1984; 72: 361-7.
50. Adedeji MO. Lymphocyte subpopulations in homozygous sickle cell anaemia. Acta Haematol 1985; 74: 10-3.
51. Ballester OF, Abdallah JM, Prasad AS. Lymphocyte subpopulation abnormalities in sickle cell anemia: a distinctive pattern from that of AIDS. Am J Hematol 1986; 21: 23-7.
52. Akbar AN, Fitzgerald-Bocarsly PA, de Sousa M, Giardina PJ, Hilgartner MW, Grady RW. Decreased natural killer activity in thalassemia major: a possible consequence of iron overload. J Immunol 1986; 136: 1635-40.
53. De Sousa M. Immune cell functions in iron overload. Clin Exp Immunol 1989; 75:1-6.
54. Gafter U, Kalechman Y, Sredni B. Induction of a subpopulation of suppressor cells by a single blood transfusion. Kidney Internat 1992; 41: 143-8.
55. Chouaib S, Chatenoud L, Klatzmann D, Fradelizi D. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol 1984; 132: 1851-7.
56. ElMasry MN, Fox EJ, Rich RR. Sequential effects of prostaglandins and interferon-gamma on differentiation of CD8+ suppressor cells. J Immunol 1987; 139:688-94.
57. Fischer A, Le Deist F, Durandy A, Griscelli C. Separation of a population of human T lymphocytes that bind prostaglandin E2 and exert a suppressor activity. J Immunol 1985; 134: 815-9.
58. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146:108-13.
59. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993; 150: 5321-9.
60. Katamura K, Shintaku N, Yamauchi Y, Fukui T, Ohshima Y, Mayumi M, et al. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 1995; 155: 4604-12.
61. Fast LD. Recipient CD8+ cells are responsible for the rapid elimination of allogeneic donor lymphoid cells. J Immunol 1996; 157: 4805-10.
62. Douillard P, Vignes C, Josien R, Chiffoleau E, Heslan JM, Proust V, et al. Reassessment of the role of CD8+ T cells in the induction of allograft tolerance by donor-specific blood transfusion. Eur J Immunol 1999; 29: 1919-24.
63. Gafter U, Kalechman Y, Sredni B. Blood transfusion enhances production of T-helper-2 cytokines and transforming growth factor beta in humans. Clin Sci 1996; 91: 519-23.
64. Giacchino F, Belardi P, Coppo R, Quarello F, Alloatti S, Pozzato M, et al. Effects of blood transfusion on cellular immunity. Proc Eur Dial Transplant Assoc 1981; 18: 465-8.
65. Akbar AN, Giardina PJ, Hilgartner MW, Grady RW. Immunological abnormalities in thalassaemia major. I. A transfusion-related increase in circulating cytoplasmic immunoglobulin-positive cells. Clin Exp Immunol 1985; 62:397-404.
66. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865-9.
67. Ghio M, Contini P, Mazzei C, Merlo A, Filaci G, Setti M, et al. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion 2001; 41: 988-96.
68. Stahl D, Lacroix-Desmazes S, Sibrowski W, Kazatchkine MD, Kaveri SV. Red blood cell transfusions are associated with alterations in self-reactive antibody repertoires of plasma IgM and IgG, independent of the presence of a specific immune response toward RBC antigens. Clin Immunol 2002; 105: 25-35.
69. Carstairs K. Human small lymphocyte: its possible pluripotential quality. Lancet 1962; 1: 829-31.
70. Allen LW, Svenson RH, Yachnin S. Purification of mitogenic proteins derived from Phaseolus vulgaris: isolation of potent and weak phytohemagglutinins possessing mitogenic activity. Proc Natl Acad Sci USA 1969; 63: 334-41.
71. Thomson AE, Bull JM, Robinson MA. A procedure for separating viable lymphocytes from human blood and some studies on their susceptibility to hypotonic shocks. Br J Haematol. 1966; 12:433-46.
72. Tarnvik A. A role for red cells in phytohaemagglutinin-induced lymphocyte stimulation. Acta Pathol Microbiol Scand B Microbiol Immunol 1970; 78: 733-40.
73. Tarnvik A. Red cells erythroagglutinating activity of phytohaemagglutinin, and lymphocyte stimulation. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1971; 79: 588-94.
74. Johnson RA, Smith TK, Kirkpatrick CH. Augmentation of phytohemagglutinin mitogenic activity by erythrocyte membranes. Cell Immunol 1972; 3: 186-97.
75. Nowaczyk M, Skopinska-Rozewska E. The influence of autologous erythrocytes on active T-cells rosetting with sheep red blood cells and on DNA synthesis. Arch Immunol Ther Exp (Warsz) 1981; 29: 391-6.
76. Silva A, Lopez-Botet M, Alvarez J, De Landazuri M. Enhancement of the functional activities of human T cells after their interaction with SRBC. J Immunol 1981; 126: 393-7.
77. Ebert EC. Sheep red blood cells enhance T-lymphocyte proliferation. Clin Immunol Immunopathol 1985; 37: 203-12.
78. Rugeles MT, La Via M, Goust JM, Kilpatrick JM, Hyman B, Virella G. Autologous red blood cells potentiate antibody synthesis by unfractionated human mononuclear cell cultures. Scand J Immunol 1987; 26: 119-27.
79. Virella G, Rugeles MT, Hyman B, La Via M, Goust JM, Frankis M, et al. The interaction of CD2 with its LFA-3 ligand expressed by autologous erythrocytes results in enhancement of B cell responses. Cell Immunol 1988; 116: 308-19.
80. Kalechman Y, Herman S, Gafter U, Sredni B. Enhancing effects of autologous erythrocytes on human or mouse cytokine secretion and IL-2R expression. Cell Immunol 1993; 148: 114-29.
81. Wilkinson M, Morris AG. Role of the E receptor in interferon-gamma expression: sheep erythrocytes augment interferon-gamma production by human lymphocytes. Cell Immunol 1984; 86: 109-17.
82. Sigfusson A, Souhami R. The effects of erythrocyte contamination on pokeweed mitogen induced immunoglobulin synthesis in man. J Immunol Methods 1984; 72: 167-70.
83. Jyonouchi H, Kincade PW, Misra HP. Analysis of the effects of erythrocytes on mitogen-dependent clonal proliferation of murine B lymphocytes. Cell Immunol 1984; 83: 189-98.
84. Trifiletti R, Hyman B, LaVia M, Knapp W, Virella G. The stimulation of T cells with anti-CD2 monoclonal antibodies facilitates the induction of polyclonal B-cell responses but does not enhance the activation of antigen-specific B cells. Scand J Immunol 1990; 31:25-31.
85. Shau H, Golub SH. Modulation of natural killer-mediated lysis by red blood cells. Cell Immunol 1988; 116: 60-72.
86. Yannelli JR, Thurman GB, Mrowca-Bastin A, Pennington CS, West WH, Oldham RK. Enhancement of human lymphokine-activated killer cell cytolysis and a method for increasing lymphokine-activated killer cell yields to cancer patients. Cancer Res 1988; 48:5696-700.
87. Wybran J, Dupont E. The active T rosette: an early marker for T-cell activation. Ann Immunol 1982; 133D: 211-8.
88. Hunig T. The cell surface molecule recognized by the erythrocyte receptor of T lymphocytes. Identification and partial characterization using a monoclonal antibody. J Exp Med 1985; 162: 890-901.
89. Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A 1987; 84:3365-9.
90. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983; 131:611-6.
91. Hunig T, Mitnacht R, Tiefenthaler G, Kohler C, Miyasaka M. T11TS, the cell surface molecule binding to the "erythrocyte receptor" of T lymphocytes: cellular distribution, purification to homogeneity and biochemical properties. Eur J Immunol 1986; 16: 1615-21.
92. Bernard A, Knowles RW, Naito K, Dupont B, Raynal B, Tran HC, et al. A unique epitope on the CD2 molecule defined by the monoclonal antibody 9-1: epitope-specific modulation of the E-rosette receptor and effects on T-cell functions. Hum Immunol 1986; 17: 388-405.
93. Holter W, Fischer GF, Majdic O, Stockinger H, Knapp W. T cell stimulation via the erythrocyte receptor. Synergism between monoclonal antibodies and phorbol myristate acetate without changes of free cytoplasmic Ca++ levels. J Exp Med. 1986; 163: 654-64.
94. Bierer BE, Barbosa J, Herrmann S, Burakoff SJ. Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation. J Immunol 1988; 140: 3358-63.
95. Plunkett ML, Sanders ME, Selvaraj P, Dustin ML, Springer TA. Rosetting of activated human T lymphocytes with autologous erythrocytes. Definition of the receptor and ligand molecules as CD2 and lymphocyte function-associated antigen 3 (LFA-3). J Exp Med 1987; 165: 664-76.
96. Makgoba MW, Shaw SW, Gugel EA, Sanders ME. Human T cell rosetting is mediated by LFA-3 on autologous erythrocytes. J Immunol 1987; 138:3587-9.
97. Selvaraj P, Dustin ML, Mitnacht R, Hunig T, Springer TA, Plunkett ML. Rosetting of human T lymphocytes with sheep and human erythrocytes. Comparison of human and sheep ligand binding using purified E receptor. J Immunol 1987; 139: 2690-5.
98. Ocklind G, Talts J, Lindahl-Kiessling K. Activation of human T cells by neuraminidase-galactose oxidase-treated erythrocytes involving CD2 (T11) and its complementary structure. Scand J Immunol 1988; 27: 697-704.
99. Prince HE. Requirement for both the CD3/T cell receptor complex and the CD2/lymphocyte function-associated antigen-3 adhesion system in monocyte-independent T cell activation by oxidized erythrocytes. Immunol Invest 1989; 18: 1081-93.
100. Bernard A, Tran HC, Boumsell L. Three different erythrocyte surface molecules are required for spontaneous T cell rosette formation. J Immunol 1987; 139: 18-23.
101. Hale LP, Singer KH, Haynes BF. CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells. J Immunol 1989; 143: 3944-8.
102. Groux H, Huet S, Aubrit F, Tran HC, Boumsell L, Bernard A. A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation. J Immunol 1989; 142: 3013-20.
103. Bernard A, Aubrit F, Raynal B, Pham D, Boumsell L. A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes. J Immunol 1988; 140: 1802-7.
104. Whitlow MB, Iida K, Stefanova I, Bernard A, Nussenzweig V. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol 1990; 126: 176-84.
105. Gelin C, Aubrit F, Phalipon A, Raynal B, Cole S, Kaczorek M, et al. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J 1989; 8: 3253-9.
106. Ellis NA, Tippett P, Petty A, Reid M, Weller PA, Ye TZ, et al. PBDX is the XG blood group gene. Nat Genet 1994; 8: 285-90.
107. Deckert M, Kubar J, Bernard A. CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J Immunol 1992; 148: 672-7.
108. Deckert M, Ticchioni M, Mari B, Mary D, Bernard A. The glycosylphosphatidylinositol-anchored CD59 protein stimulates both T cell receptor zeta/ZAP-70-dependent and - independent signaling pathways in T cells. Eur J Immunol 1995; 25: 1815-22.
109. Menu E, Tsai BC, Bothwell AL, Sims PJ, Bierer BE. CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation. J Immunol 1994; 153: 2444-56.
110. Wingett D, Forcier K, Nielson CP. A role for CD99 in T cell activation. Cell Immunol 1999; 193: 17-23.
111. Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C, et al. CD99 isoforms expression dictates T cell functional outcomes. FASEB J 2002; 16: 1946-8.
112. Fonseca AM, Porto G, Uchida K, Arosa FA. Red blood cells inhibit activation induced cell death and oxidative stress in human peripheral blood T lymphocytes. Blood 2001; 97: 3152-60.
113. Fonseca AM, Pereira CF, Porto G, Arosa FA. Red blood cells promote cell growth and survival of human peripheral blood T cells independently of CD58/LFA-3 and heme compounds. Cell Immunol 2003; in press.
114. Dustin ML, Selvaraj P, Mattaliano RJ, Springer TA. Anchoring mechanisms for LFA-3 adhesion glycoprotein at membrane surface. Nature 1987; 329: 846-9.
115. Selvaraj P, Dustin ML, Silber R, Low MG, Springer TA. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med 1987; 166: 1011-25.
116. Kay MM, Marchalonis JJ, Schluter SF, Bosman G. Human erythrocyte aging: cellular and molecular biology. Transfus Med Rev 1991; 5: 173-95.
117. Bratosin D, Mazurier J, Tissier JP, Estaquier J, Huart JJ, Ameisen JC, et al. Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie 1998; 80: 173-95.
118. Kondo H, Saito K, Grasso JP, Aisen P. Iron metabolism in the erythrophagocytosing Kupffer cell. Hepatology 1988; 8: 32-8.
119. Moura E, Noordermeer MA, Verhoeven N, Verheul AF, Marx JJ. Iron release from human monocytes after erythrophagocytosis in vitro: an investigation in normal subjects and hereditary hemochromatosis patients. Blood 1998; 92: 2511-9.
120. Costa LM, Moura EM, Moura JJ, de Sousa M. Iron compounds after erythrophagocytosis: chemical characterization and immunomodulatory effects. Biochem Biophys Res Commun 1998; 247: 159-65.
121. Stenzel KH, Rubin AL, Novogrodsky A. Mitogenic and comitogenic properties of hemin. J Immunol 1981; 127: 2469-73.
122. Novogrodsky A, Suthanthiran M, Stenzel KH. Immune stimulatory properties of metalloporphyrins. J Immunol 1989; 143: 3981-7.
123. Novogrodsky A, Suthanthiran M, Stenzel KH. Ferro-mitogens: Iron-containing compounds with lymphocyte-stimulatory properties. Cell Immunol 1991; 133: 295-305.
124. Stepien H, Kunert-Radek J, Stanisz A, Zerek-Melen G, Pawlikowski M. Inhibitory effect of porphyrins on the proliferation of mouse spleen lymphocytes in vitro. Biochem Biophys Res Commun 1991; 174: 313-22.
125. Wesch D, Marx S, Kabelitz D. Monocyte-dependent death of freshly isolated T lymphocytes: induction by phorbol ester and mitogens and differential effects of catalase. J Immunol 1998; 161: 1248-56.
126. Munn DH, Pressey J, Beall AC, Hodes R, Alderson MR. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages: a potential mechanism of antigen-specific peripheral lymphocyte deletion. J Immunol. 1996; 156: 523-32.
127. Loegering DJ, Raley MJ, Reho TA, Eaton JW. Macrophage dysfunction following the phagocytosis of IgG-coated erythrocytes: production of lipid peroxidation products. J Leukoc Biol 1996; 59: 357-62.
128. Raley MJ, Loegering DJ. Role of an oxidative stress in the macrophage dysfunction caused by erythrophagocytosis. Free Radic Biol Med 1999; 27: 1455-64.
129. Loegering DJ, Commins LM, Minnear FL, Gary LA, Hill LA. Effect of Kupffer cell phagocytosis of erythrocytes and erythrocyte ghosts on susceptibility to endotoxemia and bacteremia. Infect Immun 1987; 55: 2074-80.
130. Chaudhri G, Clark IA, Hunt NH, Cowden WB, Ceredig R. Effect of antioxidants on primary alloantigen-induced T cell activation and proliferation. J Immunol 1986; 137: 2646-52.
131. Rabesandratana H, Fournier AM, Chateau MT, Serre A, Dornand J. Increased oxidative metabolism in PMA-activated lymphocytes: a flow cytometric study. Int J Immunopharmacol 1992; 14: 895-902.
132. Sandstrom PA, Mannie MD, Buttke TM. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. J Leukoc Biol 1994; 55: 221-6.
133. Williams MS, Henkart PA. Role of reactive oxygen intermediates in TCR-induced death of T cell blasts and hybridomas. J Immunol 1996; 157: 2395-2402.
134. Hildeman, DA, Mitchell T, Teague TK, Henson P, Day BJ, Kappler J, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999; 10: 735-44.
135. Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J Exp Med 2002; 195: 59-70.
136. Hildeman DA, Mitchell T, Kappler J, Marrack P. T cell apoptosis and reactive oxygen species. J Clin Invest 2003; 111: 575-81.
137. Sekkat C, Dornand J, Gerber M. Oxidative phenomena are implicated in human T-cell stimulation. Immunology 1988; 63: 431-7.
138. Los M, Schenk H, Hexel K, Baeuerle PA, Droge W, Schulze-Osthoff K. IL-2 gene expression and NF-kB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995; 14: 3731-40.
139. + cells. J Leukoc Biol 1998; 63: 775-80.
140. Tatla S, Woodhead V, Foreman JC, Chain BM. The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Radic Biol Med 1999; 26: 14-24.
141. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 1998; 95: 4882-7.
142. Fonseca AM, Pereira CF, Porto G, Arosa FA. Red blood cells upregulate cytoprotective proteins and the labile iron pool in dividing human T cells despite a reduction in oxidative stress. Free Radic Biol Med in press.
143. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 1998; 10: 545-51.
144. Newton K, Strasser A. The Bcl-2 family and cell death regulation. Curr Opin Genet Dev 1998; 8: 68-75.
145. Marchetti P, Hirsch T, Zamzami N, Castedo M, Decaudin D, Susin SA, et al. Mitochondrial permeability transition triggers lymphocyte apoptosis. J Immunol 1996; 157: 4830-6.
146. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001; 2: 63-7.
147. Allen RG, Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med 2000; 28: 463-99.
148. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, et al. Ferritin: a cyto-protective antioxidant stratagem of endothelium. J Biol Chem 1992; 267: 18148-53.
149. Ferris CD, Jaffrey SR, Sawa A, Takahashi M, Brady SD, Barrow RK, et al. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1999; 3: 152-7.
150. Marini M, Frabetti F, Musiani D, Francheschi C. Oxygen radicals induce stress proteins and tolerance to oxidative stress in human lymphocytes. Int J Radiat Biol 1996; 70: 337-50.
151. Peng J, Jones GL, Watson K. Stress proteins as biomarkers of oxidative stress: effects of antioxidants supplements. Free Rad Biol Med 2000; 28: 1598-1606.
152. Döner MH, Silverstone A, Nishiyta K, de Sostoa A, Munn G, de Sousa M. Ferritin synthesis by human T lymphocytes. Science 1980; 209: 1019-20.
153. Pelosi E, Testa U, Louache F, Thompoulos P, Salvo G, Samoggia P, et al. Expression of transferr in receptors in phytohemagglutinin stimulated human lymphocytes. Evidence for a three-step model. J Biol Chem 1986; 261: 3036-42.
154. Pattanapanyasat K. Expression of cell surface transferrin receptor and intracellular ferritin after in vitro stimulation of peripheral blood T lymphocytes. Eur J Haematol 1989; 42: 454-9.
155. Testa U, Kuhn L, Petrini M, Quaranta MT, Pelosi E, Peschle C. Differential regulation of iron regulatory element-binding protein(s) in cell extracts of activated lymphocytes versus monocytes-macrophages. J Biol Chem 1991; 266: 13925-30.
156. Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, Torti FM. FER-1, an enhancer of the ferritin H gene and a target of E1A-mediated transcriptional repression. Mol Cell Biol 1995; 15: 5152-64.
157. Kathlon O, Gruenbaum Y, Cabantchik ZI. Repression of ferritin expression modulates cell responsiveness to H-ras-induced growth. Biochem Soc Trans 2002; 30: 777-80.
158. Wu K, Polack A, Dalla-Favera R. c-Myc coordinately regulates a gene expression program controlling iron homeostasis. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-Myc. Science 1999; 283: 676-9.
159. Ponka P, Beaumont C, Richardson DE. Function and regulation of transferrin in and ferritin. Sem Hematol 1998; 35: 35-54.
160. Seligman P, Kovar J, Gelfand EW. Lymphocyte proliferation is controlled by both iron availability and regulation of iron uptake pathways. Pathology 1992; 60: 19-26.
161. Or R, Kovar J, Domenico J, Gelfand EW. Essential fatty acids and iron are involved at distinct stages of the proliferative cycle but not involved in the activation of human T cells. Clin Immunol Immunopathol 1992; 62: 314-20.
162. Terada N, Or R, Szepesi A, Lucas JJ, Gelfand EW. Definition of the roles for iron and essential fatty acids in cell cycle progression in normal human T cells. Exp Cell Res 1993; 204: 260-7.
163. Kathlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. Free Rad Biol Med 2001; 33: 1037-46.
164. Lanzavecchia. A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290: 92-7.
165. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today 1999; 20: 177-80.
166. Porto B, Fonseca AM, Godinho I, Arosa FA, Porto, G. Human red blood cells have an enhancing effect on the relative expansion of CD8+ T lymphocytes in vitro. Cell Prolif 2001; 34: 359-67.
167. Zeng W, Maciejewski JP, Chen G, Risitano AM, Kirby M, Kajigaya S, et al. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br J Haematol 2002; 119: 803-9.
168. Kaaba SA, al-Harbi SA. Reduced levels of CD2+ cells and T-cell subsets in patients with sickle cell anaemia. Immunol Lett 1993; 37: 77-81.
169. Farmakis D, Giakoumis A, Aessopos A, Polymeropoulos E. Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 2003; 9: RA19-22.
170. Rueda F, Remacha A, Marti F, Pinol G, Soler J, Guanabens C, et al. Different lymphocyte activity in patients with polycythaemia vera versus secondary polycythaemia and healthy blood donors. Acta Haematol 1990; 83: 31-4.
171. Young NS. Immune pathophysiology of acquired aplastic anaemia. Eur J Haematol (Suppl) 1996; 60: 55-9.
172. Lamy T, Loughran TP Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev 1999; 13: 230-40.
173. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999; 130:591-601.
174. Bradstock KF. The use of hematopoietic growth factors in the treatment of acute leukemia. Curr Pharm Design 2002; 8(5): 343-55.
175. Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells affecting thyrocyte-immunocyte signalling: a review. Cuff Pharm Design 2001; 7(6): 451-60.
176. Xing Z. The hunt for new tuberculosis vaccines: anti-TB immunity and rational design of vaccines. Curr Pharm Design 2001; 7(11): 1015-37.